New study to test antifungal drug safety in organ transplant patients
NCT ID NCT07656493
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will observe 120 solid organ transplant recipients who have invasive fungal infections. Researchers will track how well the drug liposomal amphotericin B works and its side effects, compared to historical patients who received other antifungal treatments. The goal is to gather real-world evidence to guide better dosing and monitoring in this high-risk group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Liposomal amphotericin B (an antifungal drug)
What this could lead to
If successful, this study could provide real-world data to help doctors better treat fungal infections in transplant patients, potentially improving survival and reducing side effects.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by other factors. It is also small (120 participants) and single-center, limiting how widely findings can be applied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INVASIVE FUNGAL INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital
Chengdu, Sichuan, 610072, China
Contact Phone: •••-•••-•••• Email: •••••@•••••